The Use of Dipeptidyl Peptidase-4 Inhibitor Influences the Absorption of Intestine in Short Bowel Syndrome
试验速览
- 阶段
- 4 期
- 状态
- 终止
- 发起方
- 入组人数
- 8
- 试验地点
- 1
- 主要终点
- Improvement of intestinal absorption
研究概览
简要总结
The inhibition of Dipeptidyl peptidase-4 should increase the concentration of glucagone-like peptide 1 and 2, and the increase of the latter should increase the absorptive capacity of the intestine.
详细描述
The only effective (to some extend drug) in short bowel syndrome is Glucacone-like peptide 4. Its price is, however, to high to really change the treatment strategy for intestinal failure. The Dipeptidyl peptidase-4 inhibitor, which a drug which is commonly used in the treatment of diabetes mellitus type II, should increase the concentration of glucagone-like peptide 1 and 2, and the increase of the latter should increase the absorptive capacity of the intestine.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •patients receiving home parenteral nutrition (HPN) because of short bowel syndrome for at least 12 months
- •stable metabolic status
- •benign disease
排除标准
- •HPN < 12 months
- •metabolically unstable
- •cancer as the reason for intestinal failure
研究组 & 干预措施
DPP-4
The administration of the DPP-4 inhibitor in the form of a pill once per day
干预措施: Dipeptidyl peptidase-4 inhibitor (Drug)
结局指标
主要结局
Improvement of intestinal absorption
时间窗: 12 months
the use of DPP-4 inhibitor results in the better intestinal absorption
次要结局
未报告次要终点
研究者
Stanislaw Klek
Assoc. Prof.
Stanley Dudrick's Memorial Hospital